Dr. Xiaomin Jiang's research is focused on the chemical synthesis of nanomaterials, with the objectives of improving the preferential accumulation of therapeutics at tumor sites and developing innovative strategies to overcome the challenges associated with drug delivery. Through the synthesis of organic prodrugs and/or the coordination of inorganic drugs, he has successfully engineered drug-loaded nanosystems that enable sustained tumor targeting and achieve potent therapeutic efficacy. Leveraging these scientific advancements, Dr. Jiang has actively pursued translational research, leading to the development of a novel candidate drug for systemic delivery, which has successfully completed a Phase I clinical trial. This candidate shows promise as a potential treatment for a variety of advanced and metastatic cancers. His key scientific contributions include:

1. The development of nanomaterials capable of long circulation and tumor targeting through the coordination of easily degradable immune agonists with non-toxic metals, revealing a novel mechanism by which nanomedicines can enhance the efficacy of immune agonists.

2. The investigation of delivery mechanisms of chemotherapeutic agents by nanoscale coordination polymers, revealing their interactions with low-density lipoproteins (LDLs) in the bloodstream and their LDL receptor-dependent antitumor activity.

3. The development of drug-containing nanoscale metal-organic frameworks to extend drug retention at the tumor site and potentiate the efficacy of radiotherapy, chemotherapy, and immunotherapy.